Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Intercept's Revised NASH Trial Improves Prospects

Feb 13 2017

• By Joseph Haas

Related Content

NASH Drugs Soon May Have A Registrational Pathway, Finally

Mar 30 2015

The NASH Pipeline: Replete With Targets And New Compounds

Aug 29 2016

Genfit Says Safety/Tolerability Will Give Elafibranor An Edge In NASH

Dec 15 2016

Intercept Increases Chance Of Success In NASH Without Significant Delay

Feb 10 2017

Intercept’s NASH Phase III Enrolling Slowly; Gilead Could Gain Ground

Jan 13 2017

Searching For Surrogate Endpoints Requires Teamwork

Sep 30 2013

Endpoint Selection Could Help Determine The NASH Race

Nov 21 2016

'Clean Label' For Intercept's Ocaliva In PBC Bodes Well For NASH Claim

Jun 06 2016

Related Companies

Intercept Pharmaceuticals, Inc.

Genfit SA

Gilead Sciences, Inc.

Allergan plc

Allergan plc

Additional Topics

Clinical Trials Research & Development Drug Approval Standards Liver & Hepatic BioPharmaceutical

More from Clinical Trials

More from R&D

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window